Table 1.
Antibody responses in BNT162b2 vaccinated health care workers (HCW) without previous SARS-CoV-2 infection and non-hospitalized convalescent-phase COVID-19 patients.
| 0d | 3wk | 6wk | Convalescent | ||||||
|---|---|---|---|---|---|---|---|---|---|
| GM | Positive | GM | Positive | GM | Positive | GM | Positive | ||
| (95% CI) | (n/n) | (95% CI) | (n/n) | (95% CI) | (n/n) | (95% CI) | (n/n) | ||
| EIA | Anti-S1 IgG | 1 | 0% | 47 | 96% | 107 | 100% | 20 | 62% |
| (1.4–1.7) | (0/169) | (43–52) | (160/167) | (105–108) | (169/169) | (15–28) | (31/50) | ||
| Anti-S1 tot Ig | 2 | 4% | 37 | 96% | 86 | 100% | 23 | 82% | |
| (1.7–2.2) | (6/169) | (33–41) | (160/167) | (85–88) | (169/169) | (17–29) | (41/50) | ||
| Anti-N IgG | 2 | 4% | 2 | 7% | 2 | 5% | 17 | 66% | |
| (1.9–2.4) | (6/169) | (1.9–2.5) | (11/167) | (1.8–2.4) | (9/169) | (13–23) | (33/50) | ||
| MNT | FIN-25 | 10 | 0% | 24 | 63% | 234 | 100% | 55 | 86% |
| (10–10) | (0/169) | (21–28) | (106/167) | (210–261) | (169/169) | (42–73) | (43/50) | ||
| SR121 | 10 | 0% | 32 | 83% | 275 | 100% | 86 | 96% | |
| (10–10) | (0/84) | (27–37) | (70/84) | (234–323) | (86/86) | (67–110) | (48/50) | ||
| 85HEL | 10 | 0% | 24 | 63% | 240 | 100% | 74 | 96% | |
| (10–10) | (0/169) | (21–28) | (106/167) | (214–269) | (169/169) | (58–93) | (48/50) | ||
| HEL12-102 | 10 | 0% | 12 | 15% | 48 | 92% | 16 | 56% | |
| (10–10) | (0/169) | (11–13) | (25/167) | (45–54) | (156/169) | (14–18) | (28/50) | ||
HCW serum samples (n = 169) were collected before vaccination (0d), and three (3wk) and six (6wk; three weeks after the second vaccine dose) weeks after the first vaccine dose. Geometric means (GM), 95% confidence intervals (CI) and the number of positive samples for anti-S1 IgG and total Ig, and anti-N IgG antibodies and neutralizing antibodies is indicated. In microneutralization test (MNT) neutralization titre 20 or higher was considered positive and for calculation of geometric means a value of 10 was given for values of <20.